InflaRx (IFRX) AI Stock Analysis

• Market Cap: $73.18M
• Dividend Yield: N/A
• Average Volume (3M): 680.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 614,083
• 30 Day Avg. Volume: 680,720
• PEG Ratio: 0.00
• Price to Book (P/B): 2.29
• Price to Sales (P/S): 847.69
• P/FCF Ratio: -2.89
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 628.01
• Enterprise Value/Gross Profit: -7.64
• Enterprise Value/Ebitda: -1.00
• 1Y Price Target: $12.67
• Price Target Upside: 1062.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -0.79
• Revenue Forecast (FY): $894.70K

• Rating: 40 Underperform
• Price Target: $0.94 ▼(-13.39% Downside)

InflaRx's overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and cash flow challenges. Technical analysis indicates bearish momentum, further weighing on the stock's outlook. Valuation concerns, with a negative P/E ratio and no dividend yield, also contribute to the low score.

Positive Factors

Positive Clinical Trial Results

The successful Phase 2a results for INF904 indicate strong potential for further development, enhancing InflaRx's product pipeline and market position in treating inflammatory diseases.

Regained Nasdaq Compliance

Regaining Nasdaq compliance stabilizes InflaRx's market position, potentially improving investor confidence and ensuring continued access to capital markets.

Strong Product Pipeline

Active collaboration efforts to advance INF904 development highlight InflaRx's strategic focus on expanding its therapeutic offerings and leveraging partnerships for growth.

Negative Factors

Operational Challenges

Persistent operational losses underscore challenges in cost management, particularly in R&D, which could hinder long-term financial sustainability and growth.

Negative Cash Flow

Ongoing cash burn issues reflect difficulties in converting earnings into cash, potentially limiting InflaRx's ability to fund future growth and operations without additional financing.

Profitability Concerns

Continued negative profitability metrics indicate challenges in achieving financial stability, which may impact InflaRx's ability to sustain operations and invest in growth initiatives.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

How the Company Makes Money

InflaRx generates revenue primarily through the development and commercialization of its therapeutic products, particularly through licensing agreements, royalties, and potential milestone payments from partnerships with larger pharmaceutical companies. The company may also secure funding through government grants or research collaborations. As it advances its clinical trials and moves closer to obtaining regulatory approvals, InflaRx could also benefit from upfront payments and royalties from licensing its products to other firms for further development and marketing. Additionally, positive clinical trial results may enhance the company's valuation and potential for attracting investments or partnerships.

InflaRx Financial Statement Overview

Summary

InflaRx's financials reflect significant operational and financial challenges. The company is struggling with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.84K	165.79K	63.09K	0.00	0.00	0.00
Gross Profit	-5.17M	-3.15M	-469.17K	-627.01K	-791.26K	-812.47K
EBITDA	-39.53M	-45.55M	-42.06M	-30.31M	-53.11M	-37.90M
Net Income	-40.10M	-46.06M	-42.67M	-30.99M	-53.93M	-38.74M
Balance Sheet
Total Assets	65.16M	76.02M	120.21M	102.40M	125.14M	88.22M
Cash, Cash Equivalents and Short-Term Investments	44.65M	18.38M	12.77M	81.81M	83.41M	81.13M
Total Debt	970.86K	805.09K	1.12M	1.36M	1.43M	559.04K
Total Liabilities	19.79M	14.60M	17.63M	14.05M	19.86M	10.35M
Stockholders Equity	45.37M	61.42M	102.58M	88.35M	105.28M	77.86M
Cash Flow
Free Cash Flow	-42.63M	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
Operating Cash Flow	-42.50M	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
Investing Cash Flow	-2.69M	52.36M	-17.70M	19.36M	-25.95M	21.36M
Financing Cash Flow	27.50M	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 1.09 is above the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.18, and below the 200-day MA of 1.16, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 76.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	63 Neutral	$136.52M	3.47	24.38%	―	―	814.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABOS	50 Neutral	$112.67M	-0.84	-85.93%	―	―	-60.99%
ATRA	49 Neutral	$125.75M	7.96	―	―	51.27%	―
ANIX	49 Neutral	$112.58M	-9.92	-57.94%	―	―	11.78%
CLNN	49 Neutral	$61.69M	-1.76	―	―	-49.17%	23.37%
IFRX	40 Underperform	$73.18M	―	―	―	―	―

InflaRx Corporate Events

InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt

On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative skin disease, following the trial’s early termination earlier in 2025 after an independent monitoring committee deemed it futile on its prespecified primary endpoint. While the primary endpoint of complete target ulcer closure on two consecutive visits was not met, post-hoc analyses of 54 enrolled patients showed trends favoring vilobelimab over placebo, including higher rates of complete disease remission and ≥50% ulcer-volume reduction, statistically significant improvements in ulcer-volume and area reduction over weeks 12–26 under certain models, better patient-reported quality-of-life scores, and a generally well-tolerated safety profile; InflaRx now plans to meet with the U.S. Food and Drug Administration to discuss a potential path forward for vilobelimab in PG using alternative endpoints, but, prioritizing development of its oral C5aR inhibitor izicopan, it does not intend to commit substantial standalone resources to further PG studies and would only pursue additional development in collaboration with a partner.

The most recent analyst rating on (IFRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.

InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU

On November 10, 2025, InflaRx announced positive topline results from its Phase 2a study of INF904 in treating HS and CSU. The study demonstrated rapid and clinically meaningful improvements in patients, with no serious adverse events reported. These results highlight INF904’s potential as a transformative treatment in these conditions, supporting further development into Phase 2b trials. The company is actively engaging with potential collaborators to expedite development and capitalize on the growing interest in the C5aR mechanism.

The most recent analyst rating on (IFRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.

InflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges

InflaRx N.V. has released its unaudited condensed consolidated financial statements for the nine months ended September 30, 2025. The company reported revenues of €123,819 for the three months and €166,212 for the nine months ended September 30, 2025. Despite these revenues, the company faced significant losses, with a gross loss of €2,345,945 for the nine-month period. The financial results highlight the challenges InflaRx faces in managing its operational costs, particularly in research and development, which significantly impact its financial performance.

The most recent analyst rating on (IFRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.